Informações de Abbott Laboratories | Histórico, dados financeiros e desempenho de mercado

Mais detalhes de Abbott Laboratories Empresa

Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.

Informações da empresa

Código da empresaABT

Nome da EmpresaAbbott Laboratories

Data de listagemMar 01, 1937

Fundado em1900

CEOMr. Robert B. Ford

Número de funcionários114000

Tipo de títulosOrdinary Share

Fim do ano fiscalMar 01

Endereço100 Abbott Park Road

CidadeABBOTT PARK

Bolsa de valoresNYSE Consolidated

PaísUnited States of America

Código postal60064-3500

Telefone12246676100

Sitehttps://www.abbott.com

Código da empresaABT

Data de listagemMar 01, 1937

Fundado em1900

Executivos da empresa

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Daniel J. Starks

Independent Director

6.73M

+0.02%

Mr. Hubert L. Allen

Executive Vice President, General Counsel, Secretary

191.90K

+3.84%

Mr. Daniel Gesua Sive Salvadori

Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products

133.77K

+6.42%

Ms. Mary K. Moreland

Executive Vice President - Human Resources

95.58K

-0.82%

Ms. Lisa D. Earnhardt

Executive Vice President, Group President - Medical Devices

71.93K

--

Mr. Louis H. (Lou) Morrone

Executive Vice President - Core Diagnostics

66.88K

-1.63%

Mr. Philip P. Boudreau

Chief Financial Officer, Executive Vice President - Finance

56.91K

+44.72%

Dr. Robert J. Alpern, M.D.

Independent Director

40.80K

+4.17%

Ms. Nancy Mckinstry

Lead Independent Director

38.72K

+4.41%

Ms. Sally E. Blount, Ph.D.

Independent Director

36.66K

+4.67%

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Daniel J. Starks

Independent Director

6.73M

+0.02%

Mr. Hubert L. Allen

Executive Vice President, General Counsel, Secretary

191.90K

+3.84%

Mr. Daniel Gesua Sive Salvadori

Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products

133.77K

+6.42%

Ms. Mary K. Moreland

Executive Vice President - Human Resources

95.58K

-0.82%

Ms. Lisa D. Earnhardt

Executive Vice President, Group President - Medical Devices

71.93K

--

Mr. Louis H. (Lou) Morrone

Executive Vice President - Core Diagnostics

66.88K

-1.63%

Detalhamento da receita

Moeda: USDTempo de atualização: dom, 6 de abr

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

Diabetes Care

6.80B

16.22%

Core Laboratory

5.24B

12.48%

Adult Nutritionals

4.39B

10.46%

Pediatric Nutritionals

4.02B

9.59%

Key Emerging Markets

3.86B

9.20%

Other

17.64B

42.05%

Por RegiãoUSD

Nome

Receita

Proporção

United States

16.32B

38.91%

All other Countries

14.85B

35.39%

Germany

2.54B

6.05%

China

2.11B

5.04%

India

1.82B

4.33%

Other

4.31B

10.28%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Diabetes Care

6.80B

16.22%

Core Laboratory

5.24B

12.48%

Adult Nutritionals

4.39B

10.46%

Pediatric Nutritionals

4.02B

9.59%

Key Emerging Markets

3.86B

9.20%

Other

17.64B

42.05%

Acionista

Tempo de atualização: dom, 9 de fev

Estatísticas dos acionistas

Tipo

Estatísticas dos acionistas

Acionista

Proporção

The Vanguard Group, Inc.

9.68%

BlackRock Institutional Trust Company, N.A.

5.02%

State Street Global Advisors (US)

4.45%

Capital International Investors

3.92%

Capital Research Global Investors

3.12%

Other

73.81%

Estatísticas dos acionistas

Acionista

Proporção

The Vanguard Group, Inc.

9.68%

BlackRock Institutional Trust Company, N.A.

5.02%

State Street Global Advisors (US)

4.45%

Capital International Investors

3.92%

Capital Research Global Investors

3.12%

Other

73.81%

Tipo

Acionista

Proporção

Investment Advisor

35.63%

Investment Advisor/Hedge Fund

32.73%

Research Firm

3.15%

Pension Fund

2.28%

Bank and Trust

2.13%

Sovereign Wealth Fund

1.31%

Insurance Company

0.99%

Hedge Fund

0.89%

Individual Investor

0.48%

Other

20.41%

Participação acionária institucional

Tempo de atualização: dom, 19 de jan

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q1

4527

1.39B

80.29%

+21.54M

2024Q4

4535

1.39B

80.22%

+15.89M

2024Q3

4391

1.36B

78.29%

-11.85M

2024Q2

4400

1.36B

78.24%

-7.03M

2024Q1

4402

1.35B

77.67%

-9.71M

2023Q4

4429

1.35B

77.56%

-11.05M

2023Q3

4298

1.34B

77.39%

-25.33M

2023Q2

4297

1.35B

77.60%

-13.55M

2023Q1

4281

1.35B

77.46%

-8.61M

2022Q4

4258

1.34B

76.84%

-15.37M

Ver Mais

Atividade dos acionistas

Nome

Ações detidas

Proporção

Variação

Var. %

Data

The Vanguard Group, Inc.

167.89M

9.68%

+762.54K

+0.46%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

87.07M

5.02%

+811.85K

+0.94%

Dec 31, 2024

State Street Global Advisors (US)

77.17M

4.45%

+447.25K

+0.58%

Dec 31, 2024

Capital International Investors

67.97M

3.92%

+2.23M

+3.39%

Dec 31, 2024

Capital Research Global Investors

54.10M

3.12%

+795.07K

+1.49%

Dec 31, 2024

Geode Capital Management, L.L.C.

35.67M

2.06%

+765.64K

+2.19%

Dec 31, 2024

Wellington Management Company, LLP

26.39M

1.52%

+581.33K

+2.25%

Dec 31, 2024

JP Morgan Asset Management

25.13M

1.45%

+5.11M

+25.51%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

20.98M

1.21%

+626.72K

+3.08%

Dec 31, 2024

Wells Fargo Advisors

15.25M

0.88%

-105.40K

-0.69%

Dec 31, 2024

Ver Mais

ETFs Relacionados

Tempo de atualização: sáb, 5 de abr

Nome

Proporção

iShares U.S. Medical Devices ETF

17.41%

Invesco Pharmaceuticals ETF

5.78%

Goldman Sachs Future Health Care Equity ETF

5.19%

NYLI Healthy Hearts ETF

4.78%

Polen Capital Global Growth ETF

4.77%

AdvisorShares Focused Equity ETF

4.63%

Proshares Ultra Health Care

4.32%

Health Care Select Sector SPDR Fund

4.24%

iShares U.S. Healthcare ETF

4.15%

Fidelity MSCI Health Care Index ETF

3.85%

Ver Mais

iShares U.S. Medical Devices ETF

Proporção17.41%

Invesco Pharmaceuticals ETF

Proporção5.78%

Goldman Sachs Future Health Care Equity ETF

Proporção5.19%

NYLI Healthy Hearts ETF

Proporção4.78%

Polen Capital Global Growth ETF

Proporção4.77%

AdvisorShares Focused Equity ETF

Proporção4.63%

Proshares Ultra Health Care

Proporção4.32%

Health Care Select Sector SPDR Fund

Proporção4.24%

iShares U.S. Healthcare ETF

Proporção4.15%

Fidelity MSCI Health Care Index ETF

Proporção3.85%

Dividendo

Um total de 16.46B USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Dec 13, 2024

ABT.NB Interim Cash Dividend of gross USD 0.59 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Sep 19, 2024

ABT.NB Final Cash Dividend of gross USD 0.55 paid on Nov 15, 2024 going ex on Oct 15, 2024

Oct 15, 2024

Nov 15, 2024

Oct 15, 2024

Jun 15, 2024

ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option

Jul 15, 2024

Aug 15, 2024

Jul 15, 2024

Feb 16, 2024

ABT.NB Interim Cash Dividend of gross USD 0.55 paid on May 15, 2024 going ex on Apr 12, 2024

Apr 15, 2024

May 15, 2024

Apr 12, 2024

Dec 15, 2023

ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Feb 15, 2024 going ex on Jan 11, 2024 with reinvestment option

Jan 12, 2024

Feb 15, 2024

Jan 11, 2024

Sep 21, 2023

ABT.NB Final Cash Dividend of gross USD 0.51 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option

Oct 13, 2023

Nov 15, 2023

Oct 12, 2023

Jun 09, 2023

ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option

Jul 14, 2023

Aug 15, 2023

Jul 13, 2023

Feb 17, 2023

ABT.NB Interim Cash Dividend of gross USD 0.51 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option

Apr 14, 2023

May 15, 2023

Apr 13, 2023

Dec 09, 2022

ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option

Jan 13, 2023

Feb 15, 2023

Jan 12, 2023

Sep 15, 2022

ABT.NB Final Cash Dividend of gross USD 0.47 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option

Oct 14, 2022

Nov 15, 2022

Oct 13, 2022

Ver Mais

Desdobramento de ações

Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados

Abbott Laboratories

129.680USD

Abbott Laboratories

129.680

Visão Geral

Empresa